Merck’s fast-ascending kidney cancer drug hits a setback
Summary
Welireg’s failure in first-line kidney cancer removes a blockbuster opportunity and could leave an opening for a rival drug from Arcus Biosciences, analysts s...
Description
Welireg’s failure in first-line kidney cancer removes a blockbuster opportunity and could leave an opening for a rival drug from Arcus Biosciences, analysts s...
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source